Sgd Pharma India Profile
Key Indicators
- Authorised Capital ₹ 212.00 Cr
- Paid Up Capital ₹ 207.11 Cr
- Company Age 15 Year, 3 Months
- Last Filing with ROC 31 Dec 2023
- Open Charges ₹ 433.58 Cr
- Satisfied Charges ₹ 109.88 Cr
- Revenue Growth 13.06%
- Profit Growth -31.86%
- Ebitda 33.20%
- Net Worth 394.00%
- Total Assets 22.11%
About Sgd Pharma India
Sgd Pharma India Private Limited (SPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 13 November 2009 and has a history of 15 years and three months. Its registered office is in Mahabub Nagar, Telangana, India.
The Corporate was formerly known as Sgd Pharma India Limited. The Company is engaged in the Packaging Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2023. It's a company limited by shares with an authorized capital of Rs 212.00 Cr and a paid-up capital of Rs 207.11 Cr.
The company currently has active open charges totaling ₹433.58 Cr. The company has closed loans amounting to ₹109.88 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Sgd Pharma India Private Limited India are Soma Bhaumik as COMPANY SECRETARY and Mukul Kumar as Cfo. Deepak Sood, Philippe Pourquery, and Olivier Francois serve as directors at the Company.
Company Details
- Location
Mahabub Nagar, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U26100TG2009PTC065810
- Company No.
065810
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Nov 2009
- Date of AGM
28 Jun 2024
- Date of Balance Sheet
31 Dec 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Sgd Pharma India?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Deepak Sood ![]() | Managing Director | 27-Aug-2024 | Current |
Soma Bhaumik | Company Secretary | 24-Feb-2021 | Current |
Mukul Kumar ![]() | CFO | 25-Jul-2024 | Current |
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Philippe Pourquery | Director | 24-Jun-2024 | Current |
Olivier Francois | Director | 06-Oct-2022 | Current |
Financial Performance of Sgd Pharma India.
Sgd Pharma India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 13.06% increase. The company also saw a substantial fall in profitability, with a 31.86% decrease in profit. The company's net worth Soared by an impressive increase of 394%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Sgd Pharma India?
In 2021, Sgd Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹433.58 Cr
₹109.88 Cr
Charges Breakdown by Lending Institutions
- Sbicap Trustee Company Limited : 370.17 Cr
- State Bank Of India : 63.41 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
18 Mar 2024 | Sbicap Trustee Company Limited | ₹370.17 Cr | Open |
09 Nov 2012 | State Bank Of India | ₹63.41 Cr | Open |
24 Feb 2020 | Others | ₹0.60 M | Satisfied |
18 Feb 2012 | Icici Bank Limited | ₹30.00 Cr | Satisfied |
18 Aug 2010 | State Bank Of India | ₹3.44 Cr | Satisfied |
How Many Employees Work at Sgd Pharma India?
Sgd Pharma India has a workforce of 572 employees as of May 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Sgd Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sgd Pharma India's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.